Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology?

Chemical Biology and Drug Design

Volumn 87, Issue 3, 2016, Pages 321-334

  Farooqi, Ammad Ahmad ^a   Fayyaz, Sundas ^a   Shatynska Mytsyk, Iryna ^b   Javed, Zeeshan ^c   Jabeen, Saima ^d   Yaylim, Ilhan ^e   Gasparri, Maria Luisa ^f   Panici, Pierluigi Benedetti ^f  

^a RASHID LATIF MEDICAL COLLEGE   (Pakistan)

^b DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c Chughtais Lahore Lab   (Pakistan)

^d PMAS ARID AGRICULTURE UNIVERSITY   (Pakistan)

^e ISTANBUL UNIVERSITY   (Turkey)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; cancer; miR 34a

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 34A; MRX 34; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN; HISTONE DEACETYLASE; MICRORNA; MIRN34 MICRORNA, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER GENETICS; COLORECTAL CANCER; DNA DAMAGE; DRUG EFFICACY; DRUG SENSITIVITY; GENE TARGETING; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INOPERABLE CANCER; INTRACELLULAR SIGNALING; LIVER CANCER; METASTASIS; MOLECULAR GENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UPREGULATION; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASES; HUMANS; MICRORNAS; NEOPLASMS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTORS; WNT PROTEINS;

EID: 84960391831     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12634     Document Type: Review

References (93)

1. Wilczynska A., Bushell M., (2015) The complexity of miRNA-mediated repression. Cell Death Differ; 22: 22-33.
2. Lin S., Gregory R.I., (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer; 15: 321-333.
3. Kohlhapp F.J., Mitra A.K., Lengyel E., Peter M.E., (2015) MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. doi: 10.1038/onc.2015.89.
4. Li Z., Rana T.M., (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov; 13: 622-638.
5. Li Y., Go V.L., Sarkar F.H., (2015) The role of nutraceuticals in pancreatic cancer prevention and therapy: targeting cellular signaling, microRNAs, and epigenome. Pancreas; 44: 1-10.
6. Phuah N.H., Nagoor N.H., (2014) Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed Res Int; 2014: 804510.
7. Sethi S., Li Y., Sarkar F.H., (2013) Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets; 14: 1167-1174.
8. Tu C.C., Zhong Y., Nguyen L., Tsai A., Sridevi P., Tarn W.Y., Wang J.Y., (2015) The kinase ABL phosphorylates the microprocessor subunit DGCR8 to stimulate primary microRNA processing in response to DNA damage. Sci Signal; 8: ra64.
9. Navarro F., Lieberman J., (2015) miR-34 and p53: new insights into a complex functional relationship. PLoS ONE; 10: e0132767.
10. Cui X., Wu Y., Wang Z., Liu X., Wang S., Qin C., (2015) MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Tumour Biol; 36: 3887-3893.
11. Hong J.H., Roh K.S., Suh S.S., Lee S., Sung S.W., Park J.K., Byun J.H., Kang J.H., (2015) The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients. Tumour Biol. doi: 10.1007/s13277-015-3428-9.
12. Hu C.E., Liu Y.C., Zhang H.D., Huang G.J., (2014) The RNA-binding protein PCBP2 facilitates gastric carcinoma growth by targeting miR-34a. Biochem Biophys Res Commun; 448: 437-442.
13. Herbert K.J., Cook A.L., Snow E.T., (2014) SIRT1 modulates miRNA processing defects in p53-mutated human keratinocytes. J Dermatol Sci; 74: 142-149.
14. Roy A., Zhang M., Saad Y., Kolattukudy P.E., (2013) Antidicer RNAse activity of monocyte chemotactic protein-induced protein-1 is critical for inducing angiogenesis. Am J Physiol Cell Physiol; 305: C1021-C1032.
15. Hu C.E., Liu Y.C., Zhang H.D., Huang G.J., (2014) JMJD2A predicts prognosis and regulates cell growth in human gastric cancer. Biochem Biophys Res Commun; 449: 1-7.
16. Liu Y.W., Sun M., Xia R., Zhang E.B., Liu X.H., Zhang Z.H., Xu T.P., De W., Liu B.R., Wang Z.X., (2015) LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis; 6: e1802.
17. Akhurst R.J., Hata A., (2012) Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov; 11: 790-811.
18. Yang P., Li Q.J., Feng Y., Zhang Y., Markowitz G.J., Ning S., Deng Y., Zhao J., Jiang S., Yuan Y., Wang H.Y., Cheng S.Q., Xie D., Wang X.F., (2012) TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell; 22: 291-303.
19. Genovese G., Ergun A., Shukla S.A., Campos B., Hanna J., Ghosh P., Quayle S.N., et al,. (2012) microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov; 2: 736-749.
20. Guennewig B., Roos M., Dogar A.M., Gebert L.F., Zagalak J.A., Vongrad V., Metzner K.J., Hall J., (2014) Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-α. RNA; 20: 61-75.
21. Ma Z.L., Hou P.P., Li Y.L., Wang D.T., Yuan T.W., Wei J.L., Zhao B.T., Lou J.T., Zhao X.T., Jin Y., Jin Y.X., (2014) MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol; 36: 2481-2490.
22. Qiao P., Li G., Bi W., Yang L., Yao L., Wu D., (2015) microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer; 15: 469.
23. Luo J., Chen J., Deng Z.L., Luo X., Song W.X., Sharff K.A., Tang N., Haydon R.C., Luu H.H., He T.C., (2007) Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest; 87: 97-103.
24. Liang J., Li Y., Daniels G., Sfanos K., De Marzo A., Wei J., Li X., Chen W., Wang J., Zhong X., Melamed J., Zhao J., Lee P., (2015) LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. Mol Cancer Res; 13: 681-688.
25. Chen W.Y., Liu S.Y., Chang Y.S., Yin J.J., Yeh H.L., Mouhieddine T.H., Hadadeh O., Abou-Kheir W., Liu Y.N., (2015) MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in ras-activated prostate cancer. Oncotarget; 6: 441-457.
26. Rathod S.S., Rani S.B., Khan M., Muzumdar D., Shiras A., (2014) Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Bio; 4: 485-495.
27. Avtanski D.B., Nagalingam A., Kuppusamy P., Bonner M.Y., Arbiser J.L., Saxena N.K., Sharma D., (2015) Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner. Oncotarget; 6: 16396-16410.
28. Kim N.H., Cha Y.H., Kang S.E., Lee Y., Lee I., Cha S.Y., Ryu J.K., Na J.M., Park C., Yoon H.G., Park G.J., Yook J.I., Kim H.S., (2013) p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle; 12: 1578-1587.
29. Takeda Y., Venkitaraman A.R., (2015) Micro(mi) RNA-34a targets protein phosphatase (PP)1γ to regulate DNA damage tolerance. Cell Cycle. doi 10.1080/15384101.2015.1064202.
30. Erturk E., Cecener G., Egeli U., Tunca B., Tezcan G., Gokgoz S., Tolunay S., Tasdelen I., (2014) Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol Cell Biochem; 395: 77-88.
31. Kawai S., Amano A., (2012) BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J Cell Biol; 197: 201-208.
32. Kofman A.V., Kim J., Park S.Y., Dupart E., Letson C., Bao Y., Ding K., Chen Q., Schiff D., Larner J., Abounader R., (2013) microRNA-34a promotes DNA damage and mitotic catastrophe. Cell Cycle; 12: 3500-3511.
33. Sasaki A., Udaka Y., Tsunoda Y., Yamamoto G., Tsuji M., Oyamada H., Oguchi K., Mizutani T., (2012) Analysis of p53 and miRNA expression after irradiation of glioblastoma cell lines. Anticancer Res; 32: 4709-4713.
34. Kato M., Paranjape T., Müller R.U., Nallur S., Gillespie E., Keane K., Esquela-Kerscher A., Weidhaas J.B., Slack F.J., (2009) The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene; 28: 2419-2424.
35. Sun H., Tian J., Xian W., Xie T., Yang X., (2015) miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G. Dis Markers; 2015: 879254.
36. Li R., Shi X., Ling F., Wang C., Liu J., Wang W., Li M., (2015) MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL. Tumour Biol. doi: 10.1007/s13277-015-3445-8.
37. Chen Y., Tsai Y.H., Tseng S.H., et al,. (2013) Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Surgery; 153: 4-16.
38. Zhang C., Yao Z., Zhu M., et al,. (2012) Inhibitory effects of microRNA-34a on cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1. J Huazhong Univ Sci Technolog Med Sci; 32: 375-382.
39. Li J., Wang K., Chen X., Meng H., Song M., Wang Y., Xu X., Bai Y., (2012) Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol Biol; 13: 4.
40. Yamamura S., Saini S., Majid S., et al,. (2012) MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE; 7: e29722.
41. Bandi N., Vassella E., (2011) miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer; 10: 55.
42. Yang S., Li Y., Gao J., et al,. (2013) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene; 32: 4294-4303.
43. Achari C., Winslow S., Ceder Y., Larsson C., (2014) Expression of miR-34c induces G2/M cell cycle arrest in breast cancer cells. BMC Cancer; 14: 538.
44. Cao W., Yang W., Fan R., et al,. (2013) miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol; 35: 1287-1295.
45. Corcoran C., Rani S., O'Driscoll L., (2014) miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate; 74: 1320-1334.
46. Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M., (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate; 70: 1501-1512.
47. Yang F., Li Q.J., Gong Z.B., Zhou L., You N., Wang S., Li X.L., Li J.J., An J.Z., Wang D.S., He Y., Dou K.F., (2014) MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat; 13: 77-86.
48. Dokmanovic M., Clarke C., Marks P.A., (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res; 5: 981-989.
49. Lin L., Jiang H., Huang M., Hou X., Sun X., Jiang X., Dong X., Sun X., Zhou B., Qiao H., (2015) Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway. Oncol Rep; 34: 663-672.
50. Wu M.Y., Fu J., Xiao X., Wu J., Wu R.C., (2014) MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett; 354: 311-319.
51. Zhang S., Chen P., Huang Z., Hu X., Chen M., Hu S., Hu Y., Cai T., (2015) Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep; 5: 9787.
52. Ma W., Xiao G.G., Mao J., Lu Y., Song B., Wang L., Fan S., et al,. (2015) Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget; 6: 10432-10444.
53. Isosaka M., Niinuma T., Nojima M., Kai M., Yamamoto E., Maruyama R., Nobuoka T., Nishida T., Kanda T., Taguchi T., Hasegawa T., Tokino T., Hirata K., Suzuki H., Shinomura Y., (2015) A screen for epigenetically silenced microRNA genes in gastrointestinal stromal tumors. PLoS ONE; 10: e0133754.
54. Peng Y., Guo J.J., Liu Y.M., et al,. (2014) microRNA-34a inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep; 34. doi: 10.1042/BSR20140020.
55. Chen D., Li Y., Mei Y., Geng W., Yang J., Hong Q., Feng Z., Cai G., Zhu H., Shi S., Bai X.Y., Chen X., (2014) miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cell Mol Life Sci; 71: 4027-4042.
56. Silber J., Jacobsen A., Ozawa T., et al,. (2012) miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE; 7: e33844.
57. Garofalo M., Jeon Y.J., Nuovo G.J., et al,. (2013) MiR-34a/c-dependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS ONE; 2013: e67581.
58. Zhang Y., Schiff D., Park D., Abounader R., (2014) MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR. Bcl-xL and MET. PLoS ONE; 9: e91546.
59. Zhou J.Y., Chen X., Zhao J., Bao Z., Chen X., Zhang P., Liu Z.F., Zhou J.Y., (2014) MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett; 351: 265-271.
60. Dang Y., Luo D., Rong M., Chen G., (2013) Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS ONE; 8: e61054.
61. Siemens H., Neumann J., Jackstadt R., Mansmann U., Horst D., Kirchner T., Hermeking H., (2013) Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res; 19: 710-720.
62. Tanaka N., Toyooka S., Soh J., et al,. (2013) Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncol Rep; 29: 2169-2174.
63. Gao J., Li N., Dong Y., Li S., Xu L., Li X., Li Y., Li Z., Ng S.S., Sung J.J., Shen L., Yu J., (2014) miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene; 34: 4142-4152.
64. Rokavec M., Öner M.G., Li H., Jackstadt R., Jiang L., Lodygin D., Kaller M., Horst D., Ziegler P.K., Schwitalla S., Slotta-Huspenina J., Bader F.G., Greten F.R., Hermeking H., (2014) IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest; 124: 1853-1867.
65. Li T., Li L., Li D., Wang S., Sun J., (2015) MiR-34a inhibits oral cancer progression partially by repression of interleukin-6-receptor. Int J Clin Exp Pathol; 8: 1364-1373.
66. Li H., Rokavec M., Hermeking H., (2015) Soluble IL6R represents a miR-34a target: potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop. Oncotarget; 6: 14026-14032.
67. Lu G., Sun Y., An S., Xin S., Ren X., Zhang D., Wu P., Liao W., Ding Y., Liang L., (2015) MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Exp Mol Pathol; 99: 173-179.
68. Wang J., Wang H., Liu A., Fang C., Hao J., Wang Z., (2015) Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget; 6: 19456-19468.
69. Andrew A.S., Marsit C.J., Schned A.R., Seigne J.D., Kelsey K.T., Moore J.H., Perreard L., Karagas M.R., Sempere L.F., (2014) Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence. Int J Cancer. doi: 10.1002/ijc.29413.
70. Zhou B., Yi H., Tan J., Wu Y., Liu G., Qiu Z., (2015) Anti-proliferative effects of polyphenols from pomegranate rind (Punica granatum L.) on EJ bladder cancer cells via regulation of p53/miR-34a axis. Phytother Res; 29: 415-422.
71. Yu G., Yao W., Xiao W., Li H., Xu H., Lang B., (2014) MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res; 33: 779.
72. Pan X.M., Sun R.F., Li Z.H., Guo X.M., Qin H.J., Gao L.B., (2015) Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomarkers; 19: 198-202.
73. Zhang J., Huang X., Xiao J., Yang Y., Zhou Y., Wang X., Liu Q., et al,. (2014) Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS ONE; 9: e100055.
74. Muthiah M., Islam M.A., Lee H.J., Moon M.J., Cho C.S., Park I.K., (2015) MicroRNA delivery with osmotic polysorbitol-based transporter suppresses breast cancer cell proliferation. Int J Biol Macromol; 72: 1237-1243.
75. Ekin A., Karatas O.F., Culha M., Ozen M., (2014) Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. J Gene Med; 16: 331-335.
76. Wu X., Tai Z., Zhu Q., Fan W., Ding B., Zhang W., Zhang L., Yao C., Wang X., Ding X., Li Q., Li X., Liu G., Liu J., Gao S., (2014) Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo. Int J Nanomedicine; 9: 5431-5440.
77. Hu Q.L., Jiang Q.Y., Jin X., Shen J., Wang K., Li Y.B., Xu F.J., Tang G.P., Li Z.H., (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials; 34: 2265-2276.
78. Chen Y., Zhu X., Zhang X., Liu B., Huang L., (2010) Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther; 18: 1650-1656.
79. Tivnan A., Orr W.S., Gubala V., et al,. (2012) Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE; 7: e38129.
80. Wang S., Cao M., Deng X., Xiao X., Yin Z., Hu Q., Zhou Z., Zhang F., Zhang R., Wu Y., Sheng W., Zeng Y., (2015) Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Adv Healthc Mater; 4: 281-290.
81. Daige C.L., Wiggins J.F., Priddy L., Nelligan-Davis T., Zhao J., Brown D., (2014) Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther; 13: 2352-2360.
82. Shi S., Han L., Deng L., Zhang Y., Shen H., Gong T., Zhang Z., Sun X., (2014) Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release; 194: 228-237.
83. Deng X., Cao M., Zhang J., Hu K., Yin Z., Zhou Z., Xiao X., Yang Y., Sheng W., Wu Y., Zeng Y., (2014) Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials; 35: 4333-4344.
84. Scognamiglio I., Di Martino M.T., Campani V., Virgilio A., Galeone A., Gullà A., Gallo Cantafio M.E., Misso G., Tagliaferri P., Tassone P., Caraglia M., De Rosa G., (2014) Transferrin-conjugated SNALPs encapsulating 2′-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int; 2014: 217365.
85. Hargraves K.G., He L., Firestone G.L., (2015) Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells. Mol Carcinog. doi: 10.1002/mc.22296.
86. Zhou B., Yi H., Tan J., Wu Y., Liu G., Qiu Z., (2015) Anti-proliferative effects of polyphenols from pomegranate rind (Punica granatum L.) on EJ bladder cancer cells via regulation of p53/miR-34a axis. Phytother Res; 29: 415-422.
87. Wu H., Huang M., Liu Y., Shu Y., Liu P., (2014) Luteolin induces apoptosis by up-regulating miR-34a in human gastric cancer cells. Technol Cancer Res Treat. doi: 10.7785/tcrt.2012.500434.
88. Xia J., Duan Q., Ahmad A., Bao B., Banerjee S., Shi Y., Ma J., Geng J., Chen Z., Rahman K.M., Miele L., Sarkar F.H., Wang Z., (2012) Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets; 13: 1750-1756.
89. Zhang J., Zhang H.d., Chen L., Sun da W., Mao C.f., Chen W., Wu J.Z., Zhong S.L., Zhao J.H., Tang J.H., (2014) β-elemene reverses chemoresistance of breast cancer via regulating MDR-related microRNA expression. Cell Physiol Biochem; 34: 2027-2037.
90. Kang J., Kim E., Kim W., Seong K.M., Youn H., Kim J.W., Kim J., Youn B., (2013) Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem; 288: 27343-27357.
91. Peng X., Chang H., Gu Y., Chen J., Yi L., Xie Q., Zhu J., Zhang Q., Mi M., (2015) 3,6-dihydroxyflavone suppresses breast carcinogenesis by epigenetically regulating miR-34a and miR-21. Cancer Prev Res (Phila); 8: 509-517.
92. Toden S., Okugawa Y., Buhrmann C., Nattamai D., Anguiano E., Baldwin N., Shakibaei M., Boland C.R., Goel A., (2015) Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prev Res (Phila); 8: 431-443.
93. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., et al,. (2013) Treatment of HCV infection by targeting MicroRNA. N Engl J Med; 368: 1685-1694.